HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.

Latest From Cathy Kelly

'Price Gouging’ Would Be Monitored By COVID-19 Medical Supplies Coordinator Under US House Bill

Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.

Coronavirus COVID-19 Pricing Debate

Medicare CAR-T Payment Policy Walks Line Between Innovation and Cost Concerns

CMS proposes new DRG with higher average payment rate for CAR-T therapy but signals new technology add-on payments will no longer be awarded to supplement reimbursement. 

Pricing Strategies Regulation

With Telemedicine, Hospitals May Have More Flexible Access To 340B Drug Discounts

But should a patient with little connection to a 340B covered entity other than through a telehealth visit be considered eligible for a discounted drug under the program?

Pricing Strategies Regulation

Medicare Urged To Allow Home Infusion Plan With Direct Buying, Billing By Outside Providers

Manufacturers seek additional flexibility from Medicare to facilitate home infusions as surveys indicate patient visits to physician offices have dropped by 40% to 68% in recent weeks, signaling a decline in adherence for physician-administered drugs. 

Reimbursement Medicare

Waste Management: How Amgen’s Kyprolis Packaging Change Could Produce Savings To Medicare

Medicare Part B spending on discarded, weight-based drugs sold in single-use vials is around $725m annually. The National Academies of Science, Engineering and Medicine is evaluating strategies to reduce the waste.

Pricing Debate Medicare

Oncology Drug Prices In US, Europe Misaligned With Clinical Value Assessments

Study's finding is somewhat surprising for Europe, given the greater national involvement in drug prices in the region; ASCO and ESMO value frameworks don't appear to drive oncology pricing decisions regardless of the reimbursement system.

Health Technology Assessment Pricing Strategies
See All